COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS

12 Months Ended

Dec. 31, 2024

COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS

NOTE 4: COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS

Common Stock Options

The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.

The following schedule summarizes the changes in the Company’s stock options:

SCHEDULE OF CHANGES IN STOCK OPTION

	Options Outstanding				Weighted Average Remaining				Weighted Average
	Number Of Shares		Exercise Price Per Share		Contractual Life		Aggregate Intrinsic Value		Exercise Price Per Share
Year Ended December 31, 2024

Outstanding at January 1, 2024		2,252,809	$	0.024-0.04		5.70 years	$	78,886	$	0.04
Granted		-	$	-		-			$	-
Exercised		-	$	-		-			$	-
Expired/cancelled		-	$	-		-			$	-
Outstanding at December 31, 2024		2,252,809	$	0.024-0.04		4.70 years	$	174,855	$	0.04
Exercisable at December 31, 2024		2,252,809	$	0.024-0.04		4.70 years	$	174,855	$	0.04

Year Ended December 31, 2023

Outstanding at January 1, 2023		2,252,809	$	0.024-0.04		6.70 years	$	16,032	$	0.04
Granted		-	$	-		-			$	-
Exercised		-	$	-		-			$	-
Expired/cancelled		-	$	-		-			$	-
Outstanding at December 31, 2023		2,252,809	$	0.024-0.04		5.70 years	$	78,886	$	0.04
Exercisable at December 31, 2023		2,252,809	$	0.024-0.04		5.70 years	$	78,886	$	0.04

During the years ended December 31, 2024 and 2023, the Company recognized $0 of stock-based compensation expense related to the vesting of stock options.

Common Stock Warrants

The following schedule summarizes the changes in the Company’s stock warrants:

SCHEDULE OF CHANGES IN STOCK WARRANTS

	Warrants Outstanding					Weighted Average Remaining				Weighted Average
	Number Of Shares			Exercise Price Per Share		Contractual Life		Aggregate Intrinsic Value		Exercise Price Per Share
Years Ended December 31, 2024

Outstanding at January 1, 2024		26,134,000		$	0.06-0.10		3.54 years	$	-	$	0.0827
Granted		18,950,000		$	0.075		-	$	-	$	-
Redeemed		(500,000	)	$	-		-	$	-	$	-
Exercised		(28,619,000	)	$	-		-	$	-	$	-
Exchanged		(5,000,000	)	$	-		-	$	-	$	-
Outstanding at December 31, 2024		11,465,000		$	0.13		3 years	$	123,690	$	0.13
Exercisable at December 31, 2024		11,465,000		$	0.13		3 years	$	123,690	$	0.13

Years Ended December 31, 2023

Outstanding at January 1, 2023		26,737,500		$	0.06-0.10		1.52 years	$	-	$	0.09
Granted		28,799,000		$	0.0827		-	$	-	$	-
Redeemed		(500,000	)	$	-		-	$	-	$	-
Exercised		(7,663,000	)	$	-		-	$	-	$	-
Exchanged		(10,002,000	)	$	-		-	$	-	$	-
Expired/cancelled		(11,237,500	)	$	-		-	$	-	$	-
Outstanding at December 31, 2023		26,134,000		$	0.06-0.10		3.54 years	$	-	$	0.0827
Exercisable at December 31, 2023		26,134,000		$	0.06-0.10		3.54 years	$	-	$	0.0827

Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows:

	Year Ended		Years Ended
	December 31, 2024		December 31, 2023
Expected term	-		-
Expected volatility	-	%	-	%
Expected dividend yield	-		-
Risk-free interest rate	-	%	-	%

The Company granted 10,665,000 warrants in their Reg A+ funding in April 2023, with an exercise price of $0.0775 and a three-year term.

The Company granted 2,000,000 warrants in their Regulation A+ Offering in January 2024, with an exercise price of $0.075 and a three-year term and 5,000,000 warrants with the same terms on April 1, 2024.

In November 2024, the Company sold 11,950,000 warrants, 30% of which expire December 31, 2024 at an exercise price of $0.01 and 70% of which expire December 31, 2027 at an exercise price of $0.15 for $11,950 under Regulation D.

In 2024, the Company issued 25,336,468 shares of Common Stock in the exercise of 33,619,000 warrants and received $19,350.

Restricted Stock Units

The following schedule summarizes the changes in the Company’s restricted stock units:

	Number Of Shares			Weighted Average Grant Date Fair Value
Year Ended December 31, 2024

Outstanding at January 1, 2024		1,450,000		$	0.09
Granted		21,850,000		$	0.08
Vested		(11,475,000	)	$	-
Forfeited		-		$	-
Outstanding at December 31, 2024		11,825,000		$	0.08

Year Ended December 31, 2023

Outstanding at January 1, 2023		10,262,500		$	0.08
Granted		6,900,000		$	0.068
Vested		(15,450,000	)	$	-
Forfeited		(262,500	)	$	-
Outstanding at December 31, 2023		1,450,000		$	0.09

During the years ended December 31, 2024 and 2023, the Company recognized $918,350 and $1,239,950 in expense related to the vesting of its restricted stock units. As of December 31, 2024, the Company had $923,855 worth of expense yet to be recognized for restricted stock units not yet vested.

On January 1, 2024, the Company granted 20,000,000 restricted stock units to its Chief Executive Officer as part of his new employment agreement that vest in four equal installments over a two-year period beginning February 1, 2024. In May 2024, the Company granted 1,050,000 restricted stock units to consultants that vest through December 31, 2025. In November 2024, the Company granted 800,000 restricted stock units that vest in May 2025. During the year ended December 31, 2024, 11,475,000 of these restricted stock units vested.

On May 1, 2023, the Company granted 2,900,000 RSUs to consultants, with 25% of such RSUs vesting immediately, 25% vest on December 31, 2023, 25% vest on December 31, 2024 and the remaining 25% vest on December 31, 2025. These RSUs are valued at $263,900.

On August 4, 2023, the Chief Executive Officer rescinded 1,012,500 of which 750,000 had vested in prior years, of his fully vested RSUs.

In December 2023, the Company granted 4,000,000 immediately vested RSUs to a consultant, for which the RSUs are valued at $208,000.

VIVOS INC 10-K